Celldex Therapeutics, Inc. (NASDAQ:CLDX) Accelerates Commercial Readiness After Equity Raise; Near-Term Catalysts Ahead
![]() |
Celldex enters the next phase of pipeline execution with momentum in directional indicators and a large equity infusion that reshapes near-term funding. Technical momentum opposes mean-reversion risk while fundamentals reflect continued R&D spending and substantial cash reserves. |









